Compounds > 4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide
Page last updated: 2024-09-03

4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide and Diabetic Neuropathies

4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide has been researched along with Diabetic Neuropathies in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Leánez, S; McDonnell, C; Pol, O1

Other Studies

1 other study(ies) available for 4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide and Diabetic Neuropathies

ArticleYear
The induction of the transcription factor Nrf2 enhances the antinociceptive effects of delta-opioid receptors in diabetic mice.
    PloS one, 2017, Volume: 12, Issue:7

    Topics: Animals; Benzamides; Blood Glucose; Blotting, Western; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Enkephalin, D-Penicillamine (2,5)-; Hyperalgesia; Isothiocyanates; Male; Mice; NF-E2-Related Factor 2; Piperazines; Receptors, Opioid, delta; Sulfoxides

2017